SCHEMBL5031005

SCHEMBL5031005

O=C(NN=Cc1ccc[nH]1)C12CC3CC(CC(C3)C1)C2

nearest known ligand 0.68

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 4/20 0.58
▸ KMT2A Q03164 4/20 0.58
▸ ALDH1A1 P00352 3/20 0.58
▸ LMNA P02545 5/20 0.57
▸ HTT P42858 3/20 0.57
▸ TP53 P04637 1/20 0.57
▸ MAPT P10636 6/20 0.50
▸ KDM4E B2RXH2 2/20 0.50
▸ POLB P06746 1/20 0.50
▸ RAB9A P51151 3/20 0.49
▸ GAA P10253 1/20 0.49
▸ RECQL P46063 1/20 0.49
▸ TDP1 Q9NUW8 2/20 0.48
▸ NPC1 O15118 1/20 0.48
▸ NR2F2 P24468 1/20 0.48
▸ L3MBTL1 Q9Y468 1/20 0.48
▸ SMN1; SMN2 Q16637 1/20 0.48
▸ CA2 P00918 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5031002 1.00 MEN1 (0.58) MEN1KMT2AALDH1A1LMNAHTT
SCHEMBL14107064 0.84 MEN1 (0.43) MEN1KMT2AALDH1A1LMNAHTT
SCHEMBL5540677 0.74 MAPT (0.49) MEN1KMT2ALMNAHTTMAPT
SCHEMBL10335322 0.74 MAPT (0.63) MEN1KMT2AALDH1A1LMNAMAPT
SCHEMBL9655956 0.74 MAPT (0.63) MEN1KMT2AALDH1A1LMNAMAPT
SCHEMBL9655953 0.74 MAPT (0.63) MEN1KMT2AALDH1A1LMNAMAPT
SCHEMBL14757299 0.70 MAPT (0.75) MEN1KMT2AALDH1A1LMNAHTT
SCHEMBL10511247 0.70 RAB9A (0.74) MEN1KMT2AALDH1A1LMNAMAPT
SCHEMBL18190519 0.69 RAB9A (0.39) MEN1KMT2AALDH1A1LMNAHTT
SCHEMBL31005089 0.69 MAPT (0.78) MEN1KMT2AALDH1A1LMNAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8193168-B2 Use of a TRPM5 inhibitor to regulate insulin and GLP-1 release REDPOINT BIO CORPORATION (US) 2012-06-05 — — US claimed
US-20080306030-A1 Use of a TRPM5 Inhibitor to Regulate Insulin and GLP-1 Release REDPOINT BIO CORPORATION (US) 2008-12-11 — — US claimed
US-20070207093-A1 Hydrazone derivatives and uses thereof LINQUAGEN CORP. 2007-09-06 — — US claimed
US-8193168-B2 Use of a TRPM5 inhibitor to regulate insulin and GLP-1 release REDPOINT BIO CORPORATION (US) 2012-06-05 — — US disclosed
US-20080306030-A1 Use of a TRPM5 Inhibitor to Regulate Insulin and GLP-1 Release REDPOINT BIO CORPORATION (US) 2008-12-11 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070207093-A1 Hydrazone derivatives and uses thereof TAS2R1, TAS2R5, TAS1R1 MEN1 542/4885KMT2A 3035/4885ALDH1A1 72/4885
US-20080306030-A1 Use of a TRPM5 Inhibitor to Regulate Insulin and GLP-1 Release GLP1R, GIPR, TRPM5 MEN1 388/4885KMT2A 3727/4885ALDH1A1 4573/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback